|482.76||-1.21||-0.25%||Vol 197.49K||1Y Perf 29.70%|
|Aug 10th, 2022 13:30 DELAYED|
|6.02 1.24%||- -|
|Target Price||554.63||Analyst Rating||Strong Buy 1.46|
|Potential %||14.65||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★ 46.24|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★ 38.99|
|Price Range Ratio 52W %||71.43||Earnings Rating||—|
|Market Cap||115.86B||Earnings Date||20th Jul 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||7.72|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||647.34K|
|Avg. Monthly Volume||932.46K|
|Avg. Quarterly Volume||1.09M|
Elevance Health Inc. (NYSE: ELV) stock closed at 483.97 per share at the end of the most recent trading day (a 1.73% change compared to the prior day closing price) with a volume of 796.27K shares and market capitalization of 115.86B. Is a component of S&P 500 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Plans industry, Healthcare sector and employs 98200 people. Elevance Health Inc. CEO is Gail Koziara Boudreaux.
The one-year performance of Elevance Health Inc. stock is 29.7%, while year-to-date (YTD) performance is 4.97%. ELV stock has a five-year performance of 171.1%. Its 52-week range is between 355.4333 and 533.68, which gives ELV stock a 52-week price range ratio of 71.43%
Elevance Health Inc. currently has a PE ratio of 19.20, a price-to-book (PB) ratio of 3.28, a price-to-sale (PS) ratio of 1.05, a price to cashflow ratio of 14.30, a PEG ratio of 2.32, a ROA of 6.54%, a ROC of -% and a ROE of 18.38%. The company’s profit margin is 4.04%, its EBITDA margin is -%, and its revenue ttm is $110.50 Billion , which makes it $458.34 revenue per share.
Of the last four earnings reports from Elevance Health Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $7.72 for the next earnings report. Elevance Health Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Elevance Health Inc. is Strong Buy (1.46), with a target price of $554.63, which is +14.65% compared to the current price. The earnings rating for Elevance Health Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Elevance Health Inc. has a dividend yield of 1.06% with a dividend per share of $5.12 and a payout ratio of -%.
Elevance Health Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.52, ATR14 : 12.72, CCI20 : 99.90, Chaikin Money Flow : 0.05, MACD : 0.29, Money Flow Index : 52.89, ROC : 5.30, RSI : 55.84, STOCH (14,3) : 86.58, STOCH RSI : 1.00, UO : 51.15, Williams %R : -13.42), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Elevance Health Inc. in the last 12-months were: Charles Morgan Kendrick (Option Excercise at a value of $1 806 785), Charles Morgan Kendrick (Sold 6 328 shares of value $3 091 872 ), Peter Haytaian (Option Excercise at a value of $243 566), Peter Haytaian (Sold 17 703 shares of value $8 155 862 ), Ramiro G. Peru (Sold 990 shares of value $464 191 ), Robert L. Dixon (Sold 420 shares of value $208 799 ), Ronald W. Penczek (Option Excercise at a value of $1 171 799), Ronald W. Penczek (Sold 5 186 shares of value $2 376 461 )
Mon, 25 Jul 2022 16:30 GMT Elevance Health (ELV) Gets a Hold Rating from Morgan Stanley- TipRanks. All rights reserved.
Fri, 22 Jul 2022 09:41 GMT Elevance Health (ELV) Gets a Buy Rating from Jefferies- TipRanks. All rights reserved.
Thu, 21 Jul 2022 12:26 GMT Elevance Health (ELV) Receives a Rating Update from a Top Analyst- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.